New hope for taming dangerous CAR-T therapy side effect
NCT ID NCT07424222
Summary
This early-stage study is testing whether the drug ruxolitinib can safely and effectively treat a severe, life-threatening inflammatory condition called IEC-HS that sometimes occurs after CAR-T cell therapy for cancer. The study will enroll 16 adults who develop this syndrome after CAR-T treatment. Participants will take ruxolitinib pills twice daily for up to 8 weeks while researchers monitor their response and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.